Arvinas is a pharmaceutical company organized around developing new small molecules ? known as PROTACs (PROteolysis TArgeting Chimeras) ? aimed at degrading disease-causing cellular proteins via proteolysis. Anchored in work initiated at Yale University by one of the Founders of the firm, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting "undruggable" as well as "druggable" elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets. Focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases Many diseases are a result of rogue, uncontrolled proteins. Arvinas is tackling development of a new drug paradigm based on the elimination of these proteins by offering proteolysis-targeting chimera (PROTAC)-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body.
